Karen Vo

Karen Vo is a Principal Scientist at Addition Therapeutics, with a background in pharmacology and experience in various roles at companies such as 64x Bio, Ambys Medicines, and CRISPR Therapeutics. Karen's doctoral research focused on the use of gene editing in iPSCs to address Jacobsen Syndrome, a platelet disorder. Prior to their current position, Karen held roles as a Manager in Cell Engineering and Senior Scientist in multiple organizations. During their time at UC Irvine, Karen served as a Laboratory Manager and led research on anti-aging compounds, evaluating their effects on lifespan and healthspan.